Core Viewpoint - YD Bio Limited has entered into a binding Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., marking a significant step in its strategic transformation towards an end-to-end biotechnology ecosystem focused on cancer therapies [1][4]. Company Overview - YD Bio Limited is a biotechnology company that focuses on advancing clinical trials, new drug development, cancer prevention diagnostics, and therapies with high unmet medical needs [9]. - Safe Save Medical Cell Sciences & Technology Co., Ltd. specializes in the research and development of innovative therapeutic drugs using its proprietary Autologous Dendritic Cells/Tumor Antigens (ADCTA) technology [2][7]. Acquisition Details - The acquisition involves YD Bio Ltd acquiring 100% of the equity interests of Safe Save Cell (KY) Holdings Limited for a total consideration of NT$839,832,000 (approximately US$26.87 million) [4][5]. - The consideration will include a combination of newly issued YD Bio Ltd shares and cash, with specific shareholders receiving shares through a swap and general shareholders having the option for cash or shares [5]. Strategic Implications - The acquisition is expected to enhance YD Bio's R&D capabilities, accelerate entry into new therapeutic areas, and expand market reach in cell and gene therapies [4]. - SSMC's late-stage clinical assets and expertise in ADCTA technology align with YD Bio's vision to expand beyond diagnostics into innovative therapeutic solutions [4]. Clinical Applications - SSMC is advancing its Phase III clinical application of autologous dendritic cell immunocell therapy in glioblastoma, collaborating with nine medical centers in Taiwan [3]. - The therapy targets patients with Stage IV solid tumors and those with earlier-stage tumors unresponsive to standard treatments, covering various cancers including ovarian, breast, lung, colorectal, pancreatic, and glioblastoma [3]. Timeline and Conditions - The completion of the acquisition is subject to customary closing conditions, including due diligence and corporate restructuring, with an anticipated closing within thirty days after March 20, 2026 [6].